| 영문 | Wilms' tumor | 한글 | 윌름즈종양 |
|---|---|---|---|
| 설명 | 콩팥에서 발생하는 악성종양으로 소아에서 자주 발생한다. 흔히 소아에서 복부내종양을 발견시 중앙선을 넘어서면 신경모세포종이고, 중앙선을 넘지 않으면 윌름즈종양을 의심할 만큼 중요하고 흔한 종양이다. 대개 증상은 없는 편이며, 주로 아기의 목욕을 시켜주다가 우연히 발견된 복부내종괴 때문에 병원을 찾게 된다. 진단시 컴퓨터단층촬영으로 주위의 전이가 없는지를 확인해야 하며, 전이가 없으면 항암화학요법, 방사선치료요법, 그리고 수술요법의 병합요법에 의한 치료효과가 높다. |
||
| 영문 | mucinous tumor | 한글 | 점액종양 |
|---|---|---|---|
| 설명 | 점액으로 구성된 종양을 말하는데 주로 여성의 난소에서 발생하는 낭성(물주머니같은 종양을 말함) 종양에서 많이 볼 수 있다. |
||
| 영문 | tumor | 한글 | 종양 |
|---|---|---|---|
| 설명 | 조절할 수 없이 계속 진행되는 세포분열에 의한 조직의 새로운 증식 및 증대. 신생물. (1) 분류 A. 침윤과 전이의 유무에 따라 i)양성종양: 침윤과 전이가 없고 역형성이 낮은 세포로 구성됨. 대개 치료에 반응이 높고, 생명에 크게 지장이 없으며, 재발하는 경우도 적다. 증상은 단지 주위조직에 대한 압박정도이다. ii)악성종양: 침윤과 전이가 있고 퇴화도가 높은 세포로 구성됨. 기원세포가 상피조직일 경우 암종, 비상피성일 경우 육종으로 나누기도 한다. 치료에 잘 반응하지 않고, 재발을 잘 하며, 생존율이 낮다. 흔히 말하는 “암”을 의미한다. B. 조직학적 특징에 따라 샘종, 지방종, 근종 등으로 나누기도 한다. (2) 병리조직학적 특징 A. 육안적 소견 덩어리를 형성하기도 하고 정상조직에 스며들듯이 판상구조를 이루기도 하는 등 다양한 형태를 보인다. 양성의 경우 피막을 가진 경우가 많고 악성의 경우 없는 경우가 많다. 육안소견에 따라 다음과 같이 나눈다. 낭성, 융기성, 괴사성, 폴립모양, 궤양형 등이 있다. 또는 세포의 크기와 모양이 비정상적인 형태로 변화한다. 핵의 극성이 사라지고 핵의 염색성이 짙어진다. 세포질의 염색성도 변화하며 세포들간의 세포주기가 매우 다양해져 많은 세포분열을 보인다. 이러한 일련의 변화를 역형성이라 한다. 역형성의 정도에 따라 조직학적 등급을 나눈다. 또한 각 종양에 따라 각기 다른 병리조직학적 명칭을 붙인다. |
||
| TNM | primary tumor, regional nodes, metastasis [tumor staging]; thyroid node metastases; tumor node metas... |
|---|---|
| TGF | T-cell growth factor; transforming growth factor; tuboglomerular feedback; tumor growth factor |
| DF | decapacitation factor; decontamination factor; deferoxamine; deficiency factor; defined flora [anima... |
| GRF | gastrin-releasing factor; genetically related macrophage factor; gonadotropin-releasing factor; grow... |
| HSF | heat shock factor; hepatocyte stimulatory factor; histamine sensitizing factor; human serum esterase... |
| B-cell differentiating factor | <cytokine> A soluble cytokine factor produced by activated T-lymphocytes that promotes antibody production by causing proliferation and differentiation of B-cells. Interleukin-4 induces the expression of class II major histocompatibility complex and fc receptors on B-cells. It also acts on T-lymphocytes, mast cell lines, and several other haematopoietic lineage cells including granulocyte, megakaryocyte, and erythroid precursors, as well as macrophages. Acronym: IL-4 (12 Dec 1998) |
|---|---|
| B-cell stimulatory factor 2 | <cytokine> A cytokine that stimulates the growth and differentiation of human B-cells and is also a growth factor for hybridomas and plasmacytomas. It is produced by many different cells including T-cells, monocytes, and fibroblasts. A single chain 25 kD cytokine originally described as a pre B-cell growth factor, now known to have effects on a number of other cells including T-cells which are also stimulated to proliferate. An inducer of acute phase proteins and a colony-stimulating factor acting on mouse bone marrow. Acronym: IL-6 (12 Dec 1998) |
| bifidus factor | An unidentified substance associated with Lactobacillus bifidus subsp. Pennsylvanicus, present in mammalian milk. (05 Mar 2000) |
| bioaccumulation factor | Concentration of a chemical in living tissue divided by its concentration in the animal's diet. (09 Oct 1997) |
| bioconcentration factor | Concentration of a chemical in an organism divided by its concentration in the test solution or environment (for example, concentration in fish divided by concentration in water). (09 Oct 1997) |
| Bittner's milk factor | Member of the retrovirus subfamily Oncornavirinae, antigenically distinct from the murine leukaemia-sarcoma complex, that is associated with adenocarcinomatous tumours of the mammary gland, commonly latent in wild and laboratory mice and causing cancer only in genetically susceptible strains under certain hormonal influences. Synonym: Bittner agent, Bittner virus, Bittner's milk factor, mammary cancer virus of mice, milk factor, mouse mammary tumour virus. (05 Mar 2000) |
| blood clotting factor | <haematology> Any of a number of different protein factors which, when acting together, can form a blood clot shortly after platelets have broken at the site of the wound. The factors have Roman numeral names, like VII, VIII, IX, X, XI, and XIII. Defects in the genes which code for any of these factors result in genetic diseases like haemophilia, which results from a defect in the gene for factor VIII or IX. (09 Oct 1997) |
| blood coagulation factor inhibitors | Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria. (12 Dec 1998) |
| brain-derived growth factor | <growth factor> Small basic protein purified from pig brain, a member of the family of neurotrophic factors that also includes Nerve Growth Factor and neurotrophin 3. In contrast to nerve growth factor, brain-derived neurotrophic factor is predominanantly (though not exclusively) localised in the CNS. It supports the survival of primary sensory neurons originating from the neural crest and ectodermal placodes that are not responsive to NGF. In the brain brain-derived neurotrophic factor has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons. Acronym: BDGF (12 Dec 1998) |
| brain-derived neurotrophic factor | <growth factor> Small basic protein purified from pig brain, a member of the family of neurotrophic factors that also includes Nerve Growth Factor and neurotrophin 3. In contrast to nerve growth factor, brain-derived neurotrophic factor is predominanantly (though not exclusively) localised in the CNS. It supports the survival of primary sensory neurons originating from the neural crest and ectodermal placodes that are not responsive to NGF. In the brain brain-derived neurotrophic factor has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons. Acronym: BDGF (12 Dec 1998) |
| branching factor | 1,4-alpha-glucan-branching enzyme. (05 Mar 2000) |
| BT factor | <biochemistry> _ Hydroxy _ trimethyl aminobutyric acid. Compound that transports long chain fatty acids across the inner mitochondrial membrane in the form of acyl carnitine. Sometimes referred to as Vitamin Bt or Vitamin B7. (18 Nov 1997) |
| CAMP factor | A test to identify Group B beta-streptococci based on their formation of a substance (CAMP factor) that enlarges the area of haemolysis formed by streptococcal beta-haemolysin. Origin: Christie, Atkins, and Munch-Petersen, developers of the t. (05 Mar 2000) |
| capacity factor | <physics> This is the ratio of the average power output from an electric power plant to the plant's rated capacity. A capacity factor is ideally unity, but invariably less. Capacity factors vary widely between types of electric plants (for example, nuclear, solar, coal, etc.), and can even vary widely for a single type of power plant. <radiobiology> Index (typically in percent) indicating the average power supplied by an energy plant, relative to its maximum rated capacity. Synonym: plant factor, load factor. (13 Jan 1998) |
| capillary permeability factor | A mixture of bioflavonoids extracted from plants (especially citrus fruits). It reduces the permeability and fragility of capillaries and is useful in the treatment of certain cases of purpura that are resistant to vitamin C therapy. See: hesperidin, quercetin, rutin. Synonym: capillary permeability factor, citrin, permeability vitamin. (05 Mar 2000) |